Chemomab Therapeutics (CMMB) Change in Working Capital (2017 - 2018)
Chemomab Therapeutics posted quarterly Change in Working Capital of $884000.0 for Q4 2018, up 204.99% year-on-year from $289847.4 in Q4 2017, and up 204.99% on a QoQ basis from -$842000.0 in Q4 2017.
Chemomab Therapeutics (CMMB) has 2 years of Change in Working Capital data on file, last reported at $884000.0 in Q4 2018.
- For the quarter ending Q4 2018, Change in Working Capital rose 204.99% year-over-year to $884000.0; the trailing twelve-month figure through Dec 2018 stood at $884000.0 (up 204.99% YoY), and the FY2018 full-year result was $884000.0, up 204.99% from the prior year.
- Change in Working Capital for Q4 2018 stood at $884000.0, up from -$842000.0 in the prior quarter.
- Across five years, Change in Working Capital topped out at $884000.0 in Q4 2018 and bottomed at -$842000.0 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Working Capital (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 884,000.00 |
| Dec 31, 2018 | 884,000.00 |
| Dec 31, 2017 | -842,000.00 |
| Dec 31, 2017 | -842,000.00 |